Jennison Associates LLC Raises Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Jennison Associates LLC lifted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 32.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,324,410 shares of the biopharmaceutical company's stock after purchasing an additional 321,325 shares during the quarter. Jennison Associates LLC owned 2.00% of Celldex Therapeutics worth $45,017,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of CLDX. Arizona State Retirement System increased its position in shares of Celldex Therapeutics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company's stock valued at $601,000 after purchasing an additional 325 shares during the last quarter. KBC Group NV boosted its position in shares of Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 495 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Celldex Therapeutics by 9.5% in the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company's stock worth $273,000 after purchasing an additional 638 shares during the period. CANADA LIFE ASSURANCE Co raised its holdings in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company's stock worth $192,000 after purchasing an additional 955 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in Celldex Therapeutics by 23.7% during the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock valued at $291,000 after buying an additional 1,504 shares during the period.

Celldex Therapeutics Trading Up 2.3 %

NASDAQ CLDX traded up $0.59 on Friday, reaching $26.81. 258,920 shares of the stock were exchanged, compared to its average volume of 874,430. Celldex Therapeutics, Inc. has a one year low of $22.93 and a one year high of $53.18. The company's 50-day simple moving average is $30.56 and its two-hundred day simple moving average is $35.02. The firm has a market capitalization of $1.78 billion, a PE ratio of -10.24 and a beta of 1.60.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a "neutral" rating and a $45.00 price target for the company. Wolfe Research lowered Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $62.25.

Insider Buying and Selling at Celldex Therapeutics

In related news, CEO Anthony S. Marucci bought 11,500 shares of the company's stock in a transaction on Monday, November 11th. The shares were acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the transaction, the chief executive officer now owns 40,284 shares of the company's stock, valued at $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 3.80% of the company's stock.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.